131 related articles for article (PubMed ID: 38357311)
1. A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors.
Zhang C; Li J; Wu H; Huang W; Da L; Shen Y; Sun G
Front Pharmacol; 2024; 15():1356013. PubMed ID: 38357311
[TBL] [Abstract][Full Text] [Related]
2. Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.
Zhang Y; Chen Z; Liu Y; Han L; Jiang W; Wang Q; Shi J; Lu L; Li J; Zhang M; Huang Y; Yang Y; Hou X; Zhang L; Li J; Fang W; Chen G
Cancer Med; 2024 Apr; 13(7):e7175. PubMed ID: 38597130
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Shimizu T; Nakajima TE; Yamamoto N; Yonemori K; Koyama T; Kondo S; Sunakawa Y; Izawa N; Horie Y; Xiang S; Xu S; Qin L; Gong J; Liu D
Invest New Drugs; 2022 Oct; 40(5):1021-1031. PubMed ID: 35932387
[TBL] [Abstract][Full Text] [Related]
5. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Harb W; Peer CJ; Hua Q; Xu S; Lu H; Lu N; He Y; Xu T; Dong R; Gong J; Liu D
Oncologist; 2021 Sep; 26(9):e1514-e1525. PubMed ID: 33973293
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis.
Fan S; Gai C; Li B; Wang G
Oncol Lett; 2023 Aug; 26(2):351. PubMed ID: 37545619
[TBL] [Abstract][Full Text] [Related]
7. Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors.
Chen M; Jiang M; Wang X; Shen L; Li J
Expert Opin Biol Ther; 2022 Oct; 22(10):1227-1232. PubMed ID: 36124972
[TBL] [Abstract][Full Text] [Related]
8. [A phase I study of subcutaneous envafolimab (KN035) monotherapy in Chinese patients with advanced solid tumors].
Liu RR; Gu SZ; Zhou T; Lin LZ; Chen WC; Zhong DS; Liu TS; Yang N; Shen L; Xu SY; Lu N; Zhang Y; Gong ZL; Xu JM
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):898-903. PubMed ID: 37875426
[No Abstract] [Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.
Wan C; Zhang Y; Liu P; Mei X; Cheng G; Pang J; Chen S; Xu J; Malhotra J; Qian H; Du Y
J Thorac Dis; 2023 Oct; 15(10):5648-5657. PubMed ID: 37969256
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors.
Huang N; Zhao C; Hu X; Zhang C; Xiong F; Huang W; Da L; Shen Y; Wu H
Transl Cancer Res; 2022 Jan; 11(1):252-261. PubMed ID: 35261901
[TBL] [Abstract][Full Text] [Related]
15. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
16. Case report: Envafolimab causes local skin necrosis.
Liu JJ; Xu XY; Han H; Wang T; Zhang W; Cui J; Semenov M
Front Immunol; 2024; 15():1336311. PubMed ID: 38585260
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
18. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
20. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]